Мета-анализ по аспирину как профилактике преэклампсии - дозы/сроки назначения:
Administration of aspirin was associated with reduction in the risk of preterm preeclampsia (RR: 0.62, 95% CI 0.45 to 0.87), but there was no significant effect on term preeclampsia (RR: 0.92, 95% CI 0.70 to 1.21). The reduction in preterm preeclampsia was confined to the subgroup in which aspirin was initiated at ≤16 weeks' gestation and at a daily dose of ≥100 mg (RR: 0.33, 95% CI 0.19 to 0.57). This effect was also observed in the high-quality studies. The reduction in preterm preeclampsia observed in the largest trial (ASPRE; n=1620; RR: 0.38; 95% CI: 0.20 to 0.72) was similar to that in the five smaller trials in which aspirin was initiated at ≤16 weeks' gestation and at a daily dose of ≥100 mg (n=639; RR: 0.22; 95% CI: 0.07 to 0.66).
---
Am J Obstet Gynecol. 2017 Nov 11. pii: S0002-9378(17)32326-8.
Aspirin for the prevention of preterm and term preeclampsia: Systematic review and meta-analysis.
|